Literature DB >> 1450673

High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro.

K Sugimura1, T Ohno, T Kusuyama, I Azuma.   

Abstract

Arginine deiminase (AD) is a potent growth inhibitor for some but not all tumour cell lines in vitro. As AD catalyses the direct conversion of L-arginine to L-citrulline, the AD-sensitivity of various tumour cells might be attributed to the levels of urea cycle enzymes involved in L-arginine biosynthesis. This study demonstrated that human melanoma cells were highly sensitive to the growth inhibitory activity of AD. Five melanoma cell lines tested also exhibited reduced argininosuccinate synthetase (ASS) gene expression--being almost absent in four cell lines and at low level in one cell line. This resulted in an inability of the cells to utilize L-citrulline for growth. Based on the tissue-specific regulation of ASS gene, the feature of melanomas suggests that it might be possible to develop agents with strong AD activity for chemotherapeutic use for human melanomas in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1450673     DOI: 10.1097/00008390-199209000-00007

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  22 in total

Review 1.  Arginine dependence of tumor cells: targeting a chink in cancer's armor.

Authors:  M D Patil; J Bhaumik; S Babykutty; U C Banerjee; D Fukumura
Journal:  Oncogene       Date:  2016-04-25       Impact factor: 9.867

Review 2.  Pegylated arginine deiminase: a novel anticancer enzyme agent.

Authors:  Lynn Feun; Niramol Savaraj
Journal:  Expert Opin Investig Drugs       Date:  2006-07       Impact factor: 6.206

3.  Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients.

Authors:  Hua Yang; Ming Lin; Fuxia Xiong; Yu Yang; Xiu Nie; Michael A McNutt; Rouli Zhou
Journal:  Surg Today       Date:  2011-05-28       Impact factor: 2.549

Review 4.  Therapeutic interventions to disrupt the protein synthetic machinery in melanoma.

Authors:  Gregory R Kardos; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2015-09       Impact factor: 4.693

Review 5.  Arginine catabolism, liver extracts and cancer.

Authors:  Denys N Wheatley; Elaine Campbell
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

Review 6.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

Review 7.  Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.

Authors:  Macus Tien Kuo; Niramol Savaraj; Lynn G Feun
Journal:  Oncotarget       Date:  2010-08

Review 8.  Arginine deprivation as a targeted therapy for cancer.

Authors:  L Feun; M You; C J Wu; M T Kuo; M Wangpaichitr; S Spector; N Savaraj
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Reconstitution of an active arginine deiminase pathway in Mycoplasma pneumoniae M129.

Authors:  Hagai Rechnitzer; Shlomo Rottem; Richard Herrmann
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

Review 10.  Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias.

Authors:  Aboli Bhingarkar; Hima V Vangapandu; Sanjay Rathod; Keito Hoshitsuki; Christian A Fernandez
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.